News and Alerts

News and Alerts

This page is your source for pharmacy-related safety alerts, drug recalls, announcements of generic drug releases and other medication-related information.

LI NET 60 Day Supply Notification

Effective February 8, 2018 Medicare’s Limited Income NET program (LI NET) will limit the days supply for prescription drugs to no more than a 60-day dispense per fill. The maximum days supply for the below mentioned scenarios, will remain the same:

  • Hepatitis C drugs- maximum days supply is 30
  • Opioids- maximum days supply is 30
  • Unconfirmed beneficiaries (beneficiaries who have not been deemed eligible for LI NET)-maximum days supply is 34

Opioid Limitation Change Notification

Starting February 1, 2018, Medicare’s Limited Income NET Program (LI NET) will limit opioid prescription pain medications that can be filled at one time to a 30-day supply.

Med-Edit Update Notification

Beginning Jan. 1, 2018, Humana Pharmacy Solutions will make enhancements to the opioid utilization program point-of-sale edits based on the opioid thresholds below. Please note: Patients with cancer or in hospice will not be flagged for this edit.

Nuedexta to require prior authorization effective May 1, 2018

Effective May 1, 2018, Humana will add a prior authorization requirement to Nuedexta (dextromethorphan hydrobomide and quinidine sulfate) on its Medicare formularies.

Prescribers with patients currently taking Nuedexta will not be impacted by this change. Those patients will be able to continue taking the medication until the end of the plan year. On May 1, all patients with new prescriptions must have a prior authorization for Nuedexta for the claim to be covered.

Prescribers with questions regarding this change may call the Humana Clinical Pharmacy Review team at 1-800-555-CLIN (1-800-555-2546) Monday through Friday, 8 a.m. to 8 p.m. Eastern time.

Drug recall notice for EpiPen and EpiPen Jr Auto-Injector

We want to alert you to a recall of EpiPen and EpiPen Jr. (epinephrine injections USP), effective March 31, 2017. We recommend you review your medical records and contact all patients for whom you have prescribed EpiPen and EpiPen Jr Auto-Injectors to warn them of the possible problem.

Meridian Medical Technologies and Mylan voluntarily recalled EpiPen and EpiPen Jr (0.3 mg and 0.15 mg strengths) Auto-Injectors currently on the market. This recall was initiated due to reports of possible device malfunctions that could result in the devices failing to activate or requiring increased force to activate in an emergency or life-threatening situation.

The recall includes the NDC and lot numbers in the table below.

NDC Product Lot Expiration Configuration/Count

49502-501-02

49502-500-02

EpiPen Jr 2-Pak Auto-Injectors, 0.15 mg;

EpiPen 2-Pak Auto-Injectors, 0.3 mg

5GN767; 5GN773; 5GM631; 5GM640; 6GN215; 6GM082; 6GM072; 6GM081; 6GM088; 6GM199; 6GM091; 6GM198; 6GM087 April 2017 through October 2017 Dosage delivery

Patients should check the lot numbers on their cartons or devices to see if their EpiPen and EpiPen Jr Auto-Injectors are affected by this recall. If they have been recalled, patients should contact Stericycle at 1-877-650-3494 for replacements. Representatives are available Monday through Friday, 8 a.m. to 10 p.m. and Saturday and Sunday, 8 a.m. to 5 p.m. Eastern time.

Those patients who call in will receive voucher codes for their free replacement products. Stericycle will provide prepaid return packages to ship the recalled product back to the company. Patients should not return any devices affected by the recall until they have their replacements in hand. They may receive either EpiPen and EpiPen Jr Auto-Injector or the authorized generic at the pharmacy as a replacement based on availability. The authorized generic has the same drug formulation and operating system and is therapeutically equivalent to the EpiPen and EpiPen Jr Auto-Injector. Patients with questions regarding this recall can contact Mylan Customer Relations at 1-800-796-9526. Representatives are available Monday through Friday from 8 a.m. to 8 p.m. Eastern time or by email at customer.service@mylan.com.

Drug recall notice for Ventolin HFA (albuterol) inhalers

We want to alert you to a recall of Ventolin HFA (albuterol) inhalers, effective April 5, 2017. We recommend you review your medical records and contact all patients for whom you have prescribed Ventolin HFA (albuterol) inhalers to warn them of the following possible problem.

GlaxoSmithKline (GSK) voluntarily recalled more than 593,000 Ventolin HFA (albuterol) inhalers currently on the market. This recall was initiated due to a defect in certain lots of the inhaler that causes the product to deliver fewer doses than indicated. The defect does not pose a danger to patients; so, they are not being asked to return inhalers they have purchased.

The recall includes the NDC and lot numbers in the table below.

NDC Product Lot Expiration Configuration/Count

0173-0682-20

Ventolin HFA 200D

6ZP9848, 6ZP0003, 6ZP9944 March 2018 through April 2018 Dosage delivery

If patients are concerned their inhalers are not working properly, they should contact their dispensing pharmacy for guidance. No guidance was provided from the manufacturer at time of publication.

Humana announces changes to 2017 formularies

Beginning Jan. 1, 2017, certain drugs will have new limitations or will require utilization management under the Humana Medicare formularies for the 2017 plan year. These changes could mean higher costs or new requirements for Humana members who use these drugs. Humana encourages the use of generic and cost-effective brand medications whenever possible.

Formulary changes

Below are links to charts that show some commonly used medications that will be impacted by the Humana Medicare formulary changes in 2017 (e.g., prior authorization (PA) requirements, step therapy (ST) modifications and nonformulary (NF) changes). Humana members are asked to talk to their physicians and health care professionals about possible alternatives.

Humana to only cover brand-name Voltaren Gel on its Medicare formularies

Effective immediately, Humana will not cover generic Voltaren gel. Brand-name Voltaren Gel can be filled for members without a prior authorization.

Prescribers with questions regarding this change may call 1-800-555-CLIN (1-800-555-2546), Monday through Friday, 8 a.m. to 8 p.m. Eastern time.

Formulary changes for generic Renvela and generic Crestor

Humana has removed generic Renvela (sevelamer) from its Medicare and commercial formularies. Generic Crestor (rosuvastatin) will not be covered on Humana’s Medicare formularies.

Brand-name Renvela and Crestor will remain on Humana’s formularies.

Prescribers with questions regarding this change may call 1-800-555-CLIN (1-800-555-2546), Monday through Friday, 8 a.m. to 8 p.m. Eastern time.

Humana to remove sevelamer from Medicare formularies in April

Effective April 1, 2016, Humana will remove generic Renvela (sevelamer) from its Medicare formularies. Brand-name Renvela will remain on Humana’s formularies.

Patients currently taking the generic drug sevelamer will not be impacted by this change, and Humana will continue to cover the generic medication for these patients until the end of the plan year.

Prescribers with questions regarding this change may call 1-800-555-CLIN (1-800-555-2546), Monday through Friday, 8 a.m. to 8 p.m. Eastern time.